Yu Wang

TL;DR: Unmanipulated haploidentical HSCT achieves outcomes similar to those of ISD HSCT for AML patients in CR1, and was demonstrated to be a valid alternative as postremission treatment of intermediate- or high-risk AMl patients inCR1 lacking an identical donor.

TL;DR: Assessing the effect of rapamycin on the growth of nonregulatory and Treg populations of defined differentiation stages purified ex vivo from circulating CD4+ T cells shows that this phenomenon is not due to a selective expansion of naturally occurring Tregs, but to the capacity ofRapamycin to induce, upon TCR-mediated stimulation, suppressor functions in conventional CD4- T cells.

TL;DR: Serological analysis of recombinant cDNA expression libraries from four HCC patients identified 55 independent cDNA sequences potentially encoding HCC tumor Ags, including two proteins that were predominantly detected in testis, but not in other normal tissues, except for a weak expression in normal pancreas.

TL;DR: Haploidentical HSCT achieves outcomes similar to those of MSD-HSCT for Philadelphia-negative high-risk ALL patients in CR1, suggesting that such transplantation could be a valid alternative as post-remission treatment for high- risk ALL patientsin CR1 lacking an identical donor.

TL;DR: For pre-MRD-positive AML patients, haplo-SCT was associated with lower incidence of relapse and better survival, suggesting a stronger anti-leukemia effect.